

*Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics*

## Cellanyx Diagnostics News – Announcement of New Board Member Dr. Una Ryan

March 1, 2013

Cellanyx is pleased to announce the appointment of Dr. Una Ryan to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Dr. Una Ryan comes with tremendous business and leadership talent. Currently, Dr. Ryan is a Research Professor of Medicine at Boston University School of Medicine and serves on its Board of Visitors. Dr. Ryan was most recently President and CEO of Diagnostics For All (DFA), a non-profit organization developing inexpensive diagnostics for global health and agriculture. She was also formerly President and CEO of AVANT Immunotherapeutics, Inc, (NASDAQ) a company developing vaccines and immunotherapeutics for cancer, travelers, food safety, and global health. She serves on the board of AMRI, IQuum, Rhapsody Biologics, the Business Advisory Board of BIO Ventures for Global Health, the Business Advisory Board of Genocera, Inc., the Advisory Board of Phacilitate Vaccine Forum and the UMASS High Technology Executive Council.

Dr. Ryan holds a Ph.D. in Cellular and Molecular Biology from Cambridge University and BS degrees in Zoology, Microbiology and Chemistry from Bristol University. In 2009 she received an Honorary Doctor of Science degree from Bristol University and the Cartier Women's Initiative Award. In 2007, she received the Albert Einstein Award for outstanding achievement in the life sciences. In 2002 Her Majesty Queen Elizabeth II awarded Dr. Ryan the Order of the British Empire (OBE) for her services to the research, development and promotion of biotechnology.

Dr. Ryan is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that she will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

---

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.  
One Marina Park Drive,  
14th floor  
Boston, MA, 02210  
Main: 571.212.9991  
Email: [info@cellanyx.com](mailto:info@cellanyx.com)